Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α

European Journal of Haematology

Volumn 94, Issue 3, 2015, Pages 227-234

  Riley, Caroline H ^a   Hansen, Morten ^a   Brimnes, Marie K ^a   Hasselbalch, Hans C ^a   Bjerrum, Ole W ^a   Straten, Per thor ^a   Svane, Inge Marie ^a   Jensen, Morten Krogh ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

IFN treatment; JAK2 positive MPNs; NK cells

Indexed keywords

CD56 ANTIGEN; GAMMA INTERFERON; HYDROXYUREA; INTERLEUKIN 12; INTERLEUKIN 15; JANUS KINASE 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TUMOR NECROSIS FACTOR ALPHA; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; IL15 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; JAK2 PROTEIN, HUMAN; NCAM1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; K562 CELL LINE; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; NATURAL KILLER CELL; PATTERN RECOGNITION; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL RECOGNITION; THROMBOCYTHEMIA; BIOSYNTHESIS; CASE CONTROL STUDY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE SUBPOPULATION; MIDDLE AGED; PATHOLOGY; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD56; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HUMANS; HYDROXYUREA; IMMUNOLOGIC FACTORS; IMMUNOPHENOTYPING; INTERFERON-ALPHA; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-15; JANUS KINASE 2; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84923282770     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12420     Document Type: Article

References (35)

1. James C, Ugo V, Le Couédic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
2. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355:2452-66.
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
4. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
5. Kiladjian J-JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006;108:2037-40.
6. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, Bellucci S, Grandchamp B, Chomienne C, Fenaux P. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112:3065-72.
7. Larsen TS, Møller MB, de Stricker K, Nørgaard P, Samuelsson J, Marcher C, Andersen MT, Bjerrum OW, Hasselbalch HC. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 2009;14:331-4.
8. Larsen TS, Bjerrum OW, Pallisgaard N, Andersen MT, Møller MB, Hasselbalch HC. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. Ann Hematol 2008;87:847-50.
9. Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27:5418-24.
10. Kiladjian J-J. Mesa R A, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011;117:4706-15.
11. Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ. Interferon alpha in the treatment of philadelphia-negative chronic myeloproliferative neoplasms. status and perspectives. Curr Drug Targets 2011;12:392-419.
12. Murphy PT, McPherson S, Langabeer SE. Complete molecular remission in a polycythaemia vera patient 12 years after discontinuation of interferon-alpha. Ann Hematol 2011;90:233-4.
13. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48.
14. Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007;89:884-93.
15. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 2011;17:2619-27.
16. Caligiuri MA. Human natural killer cells. Blood 2008;112:461-9.
17. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-40.
18. Fauriat C, Long EO, Ljunggren H-G, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010;115:2167-76.
19. De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A 2011;108:728-32.
20. Cooper MA. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood 2001;97:3146-51.
21. Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 2009;126:458-65.
22. Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR, Wu L, Butcher EC. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 2001;166:6477-82.
23. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood 2005;106:2252-8.
24. Cooper M. NK cell and DC interactions. Trends Immunol 2004;25:47-52.
25. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003;101:3052-7.
26. + T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α. Blood 2011;118:2170-3.
27. Hansen ML, Woetmann A, Krejsgaard T, et al. IFN-α primes T- and NK-cells for IL-15-mediated signaling and cytotoxicity. Mol Immunol 2011;48:2087-93.
28. Fehniger TA, Bluman EM, Porter MM, Mrózek E, Cooper MA, VanDeusen JB, Frankel SR, Stock W, Caligiuri MA. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest 2000;106:117-24.
29. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
30. Morandi B, Bougras G, Muller WA, Ferlazzo G, Münz C. NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN-gamma secretion. Eur J Immunol 2006;36:2394-400.
31. Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004;5:1260-5.
32. Becknell B, Caligiuri MA. Natural killer cells in innate immunity and cancer. J Immunother 2008;31:685-92.
33. Adam C, King S, Allgeier T, Braumüller H, Lüking C, Mysliwietz J, Kriegeskorte A, Busch DH, Röcken M, Mocikat R. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood 2005;106:338-44.
34. Morandi B, Mortara L, Carrega P, Cantoni C, Costa G, Accolla RS, Mingari MC, Ferrini S, Moretta L, Ferlazzo G. NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs. Int Immunol 2009;21:599-606.
35. Mailliard RB, Alber SM, Shen H, Watkins SC, Kirkwood JM, Herberman RB, Kalinski P. IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med 2005;202:941-53.